Purpose: We assess the awareness of Brazilian women about non-contraceptive benefits of contraceptives and compare non-health with health care providers.
Material And Methods: We conducted a survey in Brazil using a questionnaire administered via Google Forms asking women to respond about the awareness of non-contraceptive benefits of combined oral contraceptives (COCs), depot-medroxyprogesterone acetate (DMPA), 52 mg levonorgestrel-releasing intrauterine system (LNG-IUS), etonogestrel (ENG)-implant, copper intrauterine device (Cu-IUD), and male condom.
Results: We received 2,068 completed questionnaires, 720 women (34.8%) aged ≤ 29 years and 236 (11.4%) were physicians or nurses. Only one third of the respondents were aware that COC use is associated with decreased risks of ovarian and endometrial cancers; 296 (16.1%) about that the use of DMPA is associated with a decreased risk of endometrial cancer, and 253 (13.8%) were aware about that the users of the Cu-IUD present lower risk of cervical cancer. We identified significant differences between non-health care providers when compared to physicians or nurses.
Conclusions: We found low awareness regarding the associated lower risk of ovarian, endometrial and cervical cancer associated with the use of some contraceptives, evidencing the need to provide more information about the non-contraceptive benefits during training for health care providers.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/13625187.2022.2054983 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Contraception for women over 40: A comprehensive guide.
Aust J Gen Pract
October 2024
MBBS, FRANZCOG, MClinEpid, MReproMed, MHealth@MedLaw, GradCertEBM, Associate Professor, Faculty of Medicine and Health Sciences, University of Melbourne, Parkville, Vic; Clinical Director, Melbourne IVF, East Melbourne, Vic.
Background: Women in their 40s experience significant reproductive health changes, requiring personalised contraception to avoid unintended high-risk pregnancies and adapt to changing health conditions.
Objective: This article examines optimal contraceptive choices for women in their 40s, considering effectiveness, ease of use, non-contraceptive benefits, side effects, contraindications and re-evaluation or discontinuation timings.
Discussion: Contraceptive choices for women in their 40s vary depending on their family planning status, underlying health conditions and risk factors.
What's inside matters: an assessment of the family planning content of digital self-care platforms.
Reprod Health
July 2024
FHI 360, 359 Blackwell Street, Suite 200, Durham, NC 27701, USA.
Background: Digital technology has proliferated rapidly in low- and middle-income countries in recent decades. This trend will likely persist as costs decrease, dramatically expanding access to reproductive health and family planning (FP) information. As many digital tools aim to support informed choice among individuals with unmet contraceptive need, it is essential that high-quality information is provided.
View Article and Find Full Text PDFExperts' view on the role of oestrogens in combined oral contraceptives: emphasis on oestetrol (E4).
Front Glob Womens Health
April 2024
Division of Obstetrics and Gynecology, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Introduction: The evolution of contraception has been crucial for public health and reproductive well-being. Over the past 60 years, combined oral contraceptives (COCs) have remained an important part of the contraceptive landscape worldwide; continued development has worked toward maintaining efficacy and improving safety.
Methods: Seven global experts convened to discuss the clinical relevance of the oestrogen in COCs, focusing on the impact of the new oestrogen, oestetrol (E4).
Health benefits of combined oral contraceptives - a narrative review.
Eur J Contracept Reprod Health Care
April 2024
Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Purpose: This review presents an update of the non-contraceptive health benefits of the combined oral contraceptive pill.
Methods: We conducted a literature search for (review) articles that discussed the health benefits of combined oral contraceptives (COCs), in the period from 1980 to 2023.
Results: We identified 21 subjective and/or objective health benefits of COCs related to (i) the reproductive tract, (ii) non-gynaecological benign disorders and (iii) malignancies.
A review of the pharmacology, clinical outcomes, and real-world effectiveness, safety, and non-contraceptive effects of NOMAC/E2.
Eur J Obstet Gynecol Reprod Biol X
March 2024
Theramex HQ UK Ltd, 50 Broadway, 5th Floor, London SW1H 0BL, UK.
Article Synopsis
- * Nomegestrol acetate + 17β-estradiol (NOMAC/E2) is a combined oral contraceptive that effectively inhibits ovulation and has unique characteristics, as outlined in clinical and real-world studies.
- * The review discusses NOMAC/E2's pharmacological effects, clinical efficacy, safety data, and non-contraceptive benefits, finding it has a long half-life, effective pregnancy prevention, and low risk for serious safety issues like venous thromboembolism.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!